Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q2 2025 value amounting to -$3.5 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses fell 15995.54% to -$3.5 million in Q2 2025 from the same period last year, while for May 2025 it was -$5.9 million, marking a year-over-year decrease of 45807.62%. This contributed to the annual value of -$5.9 million for FY2025, which is 45807.62% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Change in Accured Expenses stood at -$3.5 million for Q2 2025, which was down 15995.54% from -$886000.0 recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses' 5-year high stood at $13.2 million during Q1 2023, with a 5-year trough of -$13.1 million in Q2 2023.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses had a median value of -$1.2 million in 2021 and averaged -$702888.9.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 38075.16% in 2022, then tumbled by 241502.89% in 2023.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses stood at -$2.0 million in 2021, then grew by 9.6% to -$1.8 million in 2022, then surged by 86.11% to -$246000.0 in 2023, then plummeted by 412.6% to -$1.3 million in 2024, then crashed by 177.48% to -$3.5 million in 2025.
  • Its last three reported values are -$3.5 million in Q2 2025, -$886000.0 for Q1 2025, and -$1.3 million during Q4 2024.